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Abstract
Background: The calcium-binding 2EF-hand protein Phl p 7 from timothy grass
pollen is a highly cross-reactive pollen pan-allergen that can induce severe clinical
symptoms in allergic patients. Recently, a human monoclonal Phl p 7-specific
IgG4 antibody (mAb102.1F10) was isolated from a patient who had received
grass pollen-specific immunotherapy (SIT).
Methods: We studied epitope specificity, cross-reactivity, affinity and cross-protec-
tion of mAb102.1F10 towards homologous calcium-binding pollen allergens.
Sequence comparisons and molecular modelling studies were performed with
ClustalW and SPADE, respectively. Surface plasmon resonance measurements
were made with purified recombinant allergens. Binding and cross-reactivity of
patients’ IgE and mAb102.1F10 to calcium-binding allergens and peptides thereof
were studied with quantitative RAST-based methods, in ELISA, basophil activa-
tion and IgE-facilitated allergen presentation experiments.
Results: Allergens from timothy grass (Phl p 7), alder (Aln g 4), birch (Bet v 4),
turnip rape (Bra r 1), lamb’s quarter (Che a 3) and olive (Ole e 3, Ole e 8)
showed high sequence similarity and cross-reacted with allergic patients’ IgE.
mAb102.1F10 bound the C-terminal portion of Phl p 7 in a calcium-dependent
manner. It cross-reacted with high affinity with Ole e 3, whereas binding and
affinity to the other allergens were low. mAb102.1F10 showed limited cross-inhi-
bition of patients’ IgE binding and basophil activation. Sequence comparison and
surface exposure calculations identified three amino acids likely to be responsible
for limited cross-reactivity.
Conclusions: Our results demonstrate that a small number of amino acid differ-
ences among cross-reactive allergens can reduce the affinity of binding by a SIT-
induced IgG and thus limit cross-protection.
Referring to the WHO/IUIS Allergen Nomenclature, aller-
gens are listed according to their origin and thus annotated
to the individual allergen sources (1). However, it has turned
out to be useful to group allergens into families which are
Abbreviations
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specific immunotherapy.
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Allergy
related in terms of their sequence, three-dimensional structure
and immunological cross-reactivity (2, 3). The latter grouping
of allergens is extremely useful to explain clinical syndromes
based on the cross-reactivity of patients’ IgE antibodies and/
or T-cell receptors with structurally related allergens from
different allergen sources. For example, cross-reactivity of
the major birch pollen allergen Bet v 1 with counterparts in
various plant foods is responsible for oral allergy syndrome
and exacerbations of atopic eczema in birch pollen-allergic
patients upon ingestion of plant food containing cross-reac-
tive allergens (4–6). Other highly cross-reactive plant aller-
gens are the profilins, which are ubiquitous cytoskeletal
proteins (7–10), and the polcalcins, a family of calcium-bind-
ing allergens which may cause clinical reactions to multiple
plant pollens because they occur in pollens of most plants
and share a high degree of sequence similarity (11–14). Pol-
calcins from grass pollen seem to be the most potent primary
sensitizers, and sensitized patients show extensive cross-reac-
tivity of their IgE antibodies with related allergens in pollens
of various grasses, trees and weeds (15, 16). Although there
is extensive cross-reactivity of allergic patients’ IgE antibodies
towards allergens from the Bet v 1, profilin and polcalcin
family, it is a matter of debate whether immunotherapy with
one member of a particular allergen family cross-protects
against members of other allergen sources. For example in a
double-blind study of subcutaneous immunotherapy that
employed a ragweed extract in grass–ragweed dual-sensitized
individuals, the extract proved highly effective during the
ragweed season but with no cross-protection being observed
during the grass allergy season (17). A similar question is
whether birch pollen extract-based SIT has a protective effect
on oral allergy syndrome (OAS) to apple or hazelnut (18–
21). Some trials reported no (19) or no significant (18) effects
of birch pollen SIT to apple allergy in comparison with pla-
cebo, while other authors reported positive effects at varying
degrees (20, 21). A more recent study indicated that during
birch pollen SIT in most, but not all, food-sensitized patients,
there was an induction of allergen-specific IgG4 responses
(22). These findings are supported by another trial showing
that food-tolerant individuals had significantly higher Mal d
1 (apple)- and Cor a 1 (hazelnut)-specific IgG4/IgE ratios in
comparison with individuals with food allergy (23).
It is thus possible that the levels and qualities (i.e. cross-re-
activity, affinities) of therapy-induced IgG antibodies may be
important for cross-protection during SIT.
In this study, we analysed in detail a human monoclonal
IgG4 antibody, mAb102.1F10, specific for polcalcin from
timothy grass pollen, Phl p 7, which was isolated by molecu-
lar cloning from a single isolated B cell from a grass pollen-
allergic patient who had received grass pollen SIT (24).
mAb102.1F10 was shown to bind with high affinity to Phl p
7 and to inhibit allergic patients’ IgE binding to Phl p 7 as
well as Phl p 7-induced basophil activation and IgE-facili-
tated allergen presentation (24). Here, we investigated the
cross-reactivity of mAb102.1F10 with related calcium-bind-
ing allergens from tree and weed pollens, determined its
affinity towards the cross-reactive allergens and mapped its
binding site on Phl p 7. Our results reveal a very limited
cross-reactivity of mAb102.1F10. Only few exchanges of
surface-exposed amino acids on the mAb102.1F10 binding
site expressed by cross-reactive allergens appear necessary to
prevent its avid binding to alternative plant sources of pol-
calcins related to Phl p 7. Thus, epitope specificities that lead
to different affinities of binding of SIT-induced IgG may be
critical for cross-protection.
Materials and methods
Recombinant allergens, synthetic peptides, antibodies,
antisera and patients sera
Recombinant timothy grass pollen allergen Phl p 7 (15) was
obtained from Biomay AG (Vienna, Austria). Recombinant
Ole e 8 (25) from olive pollen and Bra r 1 from turnip rape
pollen were expressed in Escherichia coli and purified by
nickel-affinity chromatography (26). Recombinant Che a 3
(27) from lamb’s-quarters’ pollen was expressed and purified
as described (28). Recombinant Bet v 4 (29) from birch pol-
len, Aln g 4 (30) from alder pollen and Ole e 3 (31) from
olive pollen were cloned into the bacterial expression vector
pET151 (Life Technologies, Carlsbad, CA, USA) and
expressed in BL21 star (DE3) cells. The protein was purified
using HisTrap FF crude columns (GE Healthcare, Little
Chalfont, UK), followed by size exclusion chromatography
using an S200 column (GE Healthcare). Two synthetic
peptides that span the N-terminal EF-hand 1 (peptide 1) and
C-terminal EF-hand 2 (peptide 2) of Phl p 7 (aa 2–37, aa 37–
78) were synthesized (32).
Recombinant Phl p 7-specific IgG4 (mAb102.1F10) was
isolated from a SIT-treated grass pollen-allergic patient and
purified as described (24, 33). Rabbit anti-Phl p 7, anti-pep-
tide 1 and anti-peptide 2 antisera were obtained by immu-
nization of rabbits (32).
Sera from grass pollen-allergic patients with sensitization
to Phl p 7 were analysed in an anonymized manner with per-
mission from the Ethics Committee of the Medical University
of Vienna (EK641/2014).
Quantitative binding of allergic patients’ IgE and
mAb102.1F10 to EF-hand allergens
EF-hand allergens (Phl p 7, Aln g 4, Bet v 4, Bra r 1, Che a
3, Ole e 3, Ole e 8) and BSA (negative control) were dotted
to nitrocellulose strips (1 lg/dot) (Schleicher & Schuell, Das-
sel, Germany) and incubated with sera from 14 Phl p 7-aller-
gic patients (diluted 1 : 5), with serum from a nonallergic
individual, with mAb102.1F10 and control IgG4 (1 lg/strip;
Sigma-Aldrich, St. Louis, MO, USA) and with Phl p 7-speci-
fic rabbit antiserum and control antiserum raised against Der
p 2 from house dust mite. Bound human IgG4 antibodies
were detected with a mouse monoclonal anti-human IgG4
antibody (PharMingen, San Diego, CA, USA), followed by a
125I-labelled rabbit anti-mouse antiserum (Perkin Elmer, Wal-
tham, MA, USA), whereas bound rabbit antibodies were
detected with 125I-labelled goat anti-rabbit antisera (Perkin
Elmer). Bound patients’ IgE antibodies were detected with
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125I-labelled anti-human IgE (BSM Diagnostica, Vienna,
Austria) (data not shown). Bound 125I-labelled antibodies
were quantified with a gamma counter (Wizzard, Automatic
Gamma Counter; Wallac, Uppsala, Sweden), and results rep-
resent mean counts per minute (cpm)/dot (Fig. 1A).
Cross-reactivity of mAb102.1F10 to Phl p 7 and related
EF-hand allergens
ELISA plates (Nunc; Maxisorp, Roskilde, Denmark) were
coated with Phl p 7 (0.1 lg/well in 0.1 M bicarbonate buffer,
pH 9.6). After washing with buffer A (PBS/0.05% vol/vol
Tween-20) and blocking with buffer B (PBS/1% wt/vol
BSA) 100 ll/well of mAb102.1F10 (0.1 lg/ml in buffer B),
which had been pre-incubated overnight with increasing
concentrations (0.048–30 lg/ml in fivefold dilutions diluted
in buffer B) of inhibitors (Phl p 7, Aln g 4, Bet v 4, Bra r
1, Che a 3, Ole e 3, Ole e 8, BSA as negative control) was
added. Binding of mAb102.1F10 was detected with a horse-
radish peroxidase (HRP)-labelled rabbit anti-human IgG
antiserum diluted in buffer B (Dako, Carpenteria, CA,
USA). The colour reaction was started by the addition of
1.7 mM 2, 20azinobis-[3-ethyl-benzothiazoline-6-sulfonic acid]
(Sigma-Aldrich) in 60 mM citric acid, 77 mM Na2H-
PO4.2H2O, 3 mM H2O2. Plates were incubated in the dark
and extinctions (optical density 405 nm) were determined
with an ELISA reader. All determinations were performed
in duplicates and mean values were calculated. Relative inhi-
bition was calculated in percentage of the maximal inhibi-
tion of mAb102.1F10 binding after pre-incubation with the
maximal concentration (30 lg/ml) of Phl p 7 (Fig. 1B).
IgE-facilitated allergen binding assay
IgE-facilitated allergen binding to CD23-expressing B cells
was determined as described (34). In brief, EF-hand allergens
(Phl p 7, Aln g 4, Bet v 4, Bra r 1, Ole e 3, Ole e 8; 0–
300 ng/ml) were incubated in triplicates with sera from Phl p
7-allergic patients (patients #16, 17, 18; Fig. 2) to allow IgE–
allergen complex formation. EBV-transformed B cells
(100.000 cells/sample) were added and the mixture was incu-
bated at room temperature. IgE binding to the cells was
detected with phycoerythrin (PE)-labelled anti-human IgE
(MACS; Miltenyi Biotec, Bergisch Gladbach, Germany) by
flow cytometry, and relative binding of mean values is
displayed.
Inhibition of allergic patients’ IgE reactivity to Phl p 7 and
related EF-hand allergens with mAb102.1F10
ELISA plates were coated with allergens (0.1 lg/well) and
pre-incubated with mAb102.1F10 (2 lg/well) or with control
IgG4 (2 lg/well; Sigma-Aldrich). Next, plates were incubated
with sera from Phl p 7-allergic patients or a nonallergic sub-
ject (diluted 1 : 5). Bound IgE antibodies were detected with
a mouse monoclonal anti-human IgE antiserum (PharMin-
gen) followed by the HRP-labelled sheep anti-mouse anti-
serum (GE Healthcare). All determinations were performed
in duplicates and mean values were calculated. Percentage
inhibitions were determined as follows: 100-(OD bound IgE
after pre-incubation with mAb102.1F10 * 100/OD bound
IgE after pre-incubation with control IgG4) (Fig. 3).
Indirect epitope mapping of mAb102.1F10
ELISA plate-bound Phl p 7 (0.1 lg/well) was pre-incubated
with rabbit antisera (1 : 20 in buffer B) raised against Phl p
7, Phl p 7 peptides 1 or 2 (Fig. 4A) (inhibitors), or a normal
rabbit serum (control). After washing, mAb102.1F10 or con-
trol IgG4 (Sigma-Aldrich) (0.1 lg/well) was added and bound
human IgG antibodies were detected with HRP-labelled rab-
bit anti-human IgG antibodies (Dako). All determinations
were performed in duplicates, mean ODs were calculated,
and percentage inhibitions were calculated according to the
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Figure 1 Cross-reactivity of mAb102.1F10 with Phl p 7 and related
EF-hand allergens. (A) mAb102.1F10 reactivities to nitrocellulose-
dotted 2EF-hand allergens (x-axis: Phl p 7, Aln g 4, Bet v 4, Bra r 1,
Che a 3, Ole e 3) are shown as absolute cpm values (y-axis). (B)
Specific inhibition of mAb102.1F10 binding (y-axis: % inhibition) to
Phl p 7 after pre-incubation with inhibitors (x-axis: Phl p 7, Aln g 4,
Bet v 4, Bra r 1, Che a 3, Ole e 3, Ole e 8, BSA; 30, 6, 1.2, 0.24,
0.048, 0 lg/ml).
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formula: 100 – (OD mAb102.1F10 binding after pre-incuba-
tion with inhibitors * 100/OD mAb102.1F10 binding after
pre-incubation with control) (Fig. 4B).
Sequence alignment of Phl p 7 with related EF-hand
allergens
Sequences of Phl p 7 (Swiss-Prot: O82040.1), Aln g 4 (Swiss-
Prot: O81701.1), Bet v 4 (GenBank: CAA73147.1), Bra r 1
(Swiss-Prot: P69197.1), Che a 3 (Swiss-Prot: Q84V36.1), Ole e
3 (Swiss-Prot: O81092.1) and Ole e 8 (Swiss-Prot: Q9M7R0.1)
were aligned with CLUSTALW2 (35) and revised by hand
editing (Fig. 5A). Amino acid sequence identities were
calculated (Table S1) (35), and EF-hand domains and Ca2+
binding sites were indicated according to UniProt entries.
Surface exposure analysis of Che a 3 and Phl p 7
The relative surface accessibility of individual amino acids
was calculated for both monomers of the dimer structures
using SPADE (36). For Phl p 7, the coordinates PDB:1K9U
were used, and for Che a 3, the coordinates PDB:2OPO
(chains a and b) were used. The absolute surface exposure (in
A2) as well as the relative surface exposure (in % of the maxi-
mal surface exposure of the individual residue) was calculated,
along with the average values from chains a and b (Table 1).
Results
mAb102.1F10 shows different affinity to cross-reactive EF-
hand allergens
Table S1 shows that the sequence identity among six 2EF-
hand allergens (Phl p 7, Aln g 4, Bet v 4, Bra r 1, Che a 3,
Ole e 3) was high and ranged between 67 and 91% (mean:
75.8%). Only the 4EF-hand allergen Ole e 8 showed lower
sequence identity (38–48%, mean: 43%) due to its different
length and architecture (Table S1).
The affinities of mAb102.1F10 to the purified EF-hand
allergens were measured by surface plasmon resonance mea-
surements. Phl p 7 was recognized with highest affinity (KD:
2.11 9 109 M) closely followed by Ole e 3 (KD:
6.18 9 109 M) which shares 68% sequence identity with Phl
p 7 (Table S2). Interestingly, Aln g 4, Bet v 4 and Bra r 1,
which share a similar degree of sequence identity to Phl p 7
(i.e. 67–69%) as Ole e 3, were recognized with approximately
1000 times lower affinity (KDs: Aln g 4: 7.93 9 10
6
M; Bet
v 4: 6.26 9 106 M; Bra r 1: 6.57 9 106 M) (Table S2). Ole
e 8 was bound with lowest affinity (KD~7.06 9 10
5
M)
(Table S2).
Binding of mAb102.1F10 to the EF-hand allergens depends
on the presence of protein-bound calcium
Allergic patients’ IgE reactivity to EF-hand allergens strongly
depends on protein-bound calcium (11). We therefore investi-
gated whether the binding of mAb102.1F10 to EF-hand aller-
gens is also calcium sensitive. The binding of mAb102.1F10
to nitrocellulose-dotted EF-hand allergens in the presence of
calcium reflected the surface plasmon resonance experiments,
showing that Phl p 7 and Ole e 3 reacted most strongly
whereas the binding to Aln g 4, Bet v 4, Bra r 1 and Che a 3
was more than 100-fold less (Table S3). Ole e 8 showed no
reactivity over the negative controls (i.e. BSA, control IgG4)
(Table S3). Depletion of calcium by addition of EGTA
reduced binding of mAb102.1F10 between 33.2% (Ole e 3)
and 91.3% (Phl p 7) (Table S3).
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Figure 2 Binding of immune complexes consisting of patients’ IgE
and EF-hand allergens to B cells. Relative binding (y-axes: % bind-
ing) of complexes consisting of increasing doses (x-axes: 0, 1, 3,
10, 30, 100, 300 ng/ml) of EF-hand allergens (Phl p 7, Aln g 4, Bet
v 4, Bra r 1, Ole e 3, Ole e 8) and patients’ serum IgE (patients
#16, #17, #18) to CD23-expressing B cells.
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mAb102.1F10 shows limited cross-reactivity with EF-hand
allergens, whereas allergic patients’ IgE antibodies show
broad cross-reactivity
In the dot blot assay, mAb102.1F10 strongly cross-reacted
with Phl p 7 and Ole e 3 and only weakly with Che a
3 > Bet v 4 > Bra r 1 > Aln g 4 (Fig. 1A). Next, we pre-incu-
bated mAb102.1F10 with increasing doses of EF-hand aller-
gens and tested for remaining reactivity to Phl p 7 in a
competitive inhibition ELISA (Fig. 1B). Only pre-incubation
with Phl p 7 and Ole e 3 completely blocked the binding of
mAb102.1F10 to Phl p 7, whereas pre-incubation with the
other EF-hand allergens hardly influenced its binding to Phl
p 7 (Fig. 1B). By contrast, Phl p 7-allergic patients’ poly-
clonal IgE antibodies showed extensive cross-reactivity with
2EF-hand allergens (mean IgE levels: Ole e 3 > Bet v
4 > Aln g 4 > Che a 3 and to a lower extent to Bra r 1) (data
not shown). The functional relevance of the cross-reactivity
of allergic patients’ IgE with the EF-hand allergens was
demonstrated using the IgE-facilitated allergen binding assay
where the formation of allergen–IgE complexes and their
subsequent binding to CD23 on B cells were studied. IgE
immune complexes formed with Phl p 7 and Ole e 3 gave the
strongest B-cell staining (maximum 25% binding, Fig. 2).
There was also staining with Aln g 4 and Bet v 4 but only at
high allergen concentrations and to a lesser extent (maximum
5–15% binding, Fig. 2).
Cross-inhibition of patients’ IgE binding to EF-hand
allergens by mAb102.1F10 reflects its affinity and cross-
reactivity
When we pre-incubated EF-hand allergens with
mAb102.1F10, variable degrees of inhibition of allergic
patients’ polyclonal IgE binding were observed (Fig. 3). The
inhibition of IgE binding to Phl p 7 (0–68.6%; mean inhibi-
tion 38.4%), Ole e 3 (0–80.8%; mean inhibition 39%) and
Che a 3 (0–80.8%; mean inhibition 31.7%) by mAb102.1F10
was highest, followed by Aln g 4 (0–30.8%; mean inhibition
15.3%), Bra r 1 (0–53.9%; mean inhibition: 13%) and Bet v
4 (0–25.5%; mean inhibition 13%). Almost no inhibition of
IgE binding to Ole e 8 was found.
We also investigated whether mAb102.1F10 can inhibit
EF-hand allergen-induced basophil activation using
blood samples from three Phl p 7-allergic patients
(Fig. S1A–C). mAb102.1F10 inhibited Phl p 7- and Ole
e 3-induced basophil activation by up to five times in 2
of 3 patients tested (Fig. S1A, C) but had no effect on
basophil activation induced by other EF-hand allergens
(Fig. S1 A–C).
mAb102.1F10 recognizes the C-terminal EF-hand of Phl p 7
To define the binding region of mAb102.1F10 on Phl p 7, we
performed inhibition assays using rabbit antisera raised
peptide 1 peptide 2
aa 2 aa 78
Phl p 7
A
B
aa 78aa 1
Peptides
Binding of 
mAb102.1F10 (OD) 
Inhibition of 
mAb102.1F10 
binding (%) 
Pre-
incubation 
with 
aa 37 aa 37
Rabbit α Phl p 7 0.59 46.23
Rabbit α peptide 1 0.97 12.21
Rabbit α peptide 2 0.65 41.02
Control antiserum 1.10 0.00
Figure 4 Epitope mapping of mAb102.1F10. (A) Amino acid (aa)
sequences of Phl p 7 (aa 1–78) and of Phl p 7 peptides (peptide
1: aa 2–37; peptide 2: aa 37–78) are shown. EF-hand domains
are coloured (EF-hand 1: blue; EF-hand 2: yellow) and calcium
binding sites are bold and underscored. (B) Inhibition of
mAb102.1F10 binding to Phl p 7 obtained by pre-incubation of
Phl p 7 with rabbit antisera raised against Phl p 7, peptide 1,
peptide 2, or with a control rabbit antiserum. Reaction levels of
mAb102.1F10 binding to Phl p 7 after pre-incubation with rabbit
antisera (OD levels at 405 nm) and percentage inhibition of
mAb102.1F10 binding in relation to pre-incubation with the control
antiserum are shown.
Figure 3 Inhibition of Phl p 7-allergic patients’ IgE binding to Phl
p 7 and related EF-hand allergens by mAb102.1F10. Patients’ IgE
bindings (y-axes: OD values at 405 nm  SD) to plate-bound Phl
p 7, Aln g 4, Bet v 4, Bra r 1, Che a 3, Ole e 3 and Ole e 8
after pre-incubation with mAb102.1F10 (black bars) or control
IgG4 (grey bars) are displayed for 15 Phl p 7-allergic patients (ID
1–15) (x-axes). Percentage inhibitions are shown on the bottom
of each chart (n.I.: no Inhibition). Mean percentage inhibitions for
each allergen are indicated in parentheses in the headline of each
chart.
Allergy 71 (2016) 36–46 © The Authors. Allergy Published by John Wiley & Sons Ltd. 41
Gadermaier et al. SIT-induced monoclonal IgG4
BA
D66_b
D70_b
D70_a
D66_a
R49_a
180°
R49_b
D70_b
D66_a
N58_b
S62_b
S62_a
N58_a
Q41_a
180° Q41_b
S62_b
N58_a
b
a
b
a R49_a
Che a 3
Phl p 7
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Figure 5 (A), Protein sequence alignment of Phl p 7 with
related EF-hand allergens. Identical amino acids are indicated by
dots and gaps are indicated by dashes. EF-hand domains are
coloured (EF-hand 1: blue; EF-hand 2: yellow; EF-hand 3: red;
EF-hand 4: green) and calcium binding sites are bold and under-
scored. Amino acids that according to epitope mapping may
influence binding of mAb102.1F10 are highlighted in red. Amino
acids that were excluded to contribute to differences in binding
are boxed or indicated by asterisks. (B) Ribbon and surface rep-
resentation of Phl p 7 and Che a 3 dimers (chain a and chain
b). Residues possibly involved in binding of mAb102.1F10 (see
Fig. 5A, red) are highlighted on the molecular surface of Phl p
7 (green) and of Che a 3 (blue). The dimer structures are
shown as ribbon and as surface representation in the same ori-
entation (Surface_Front) and rotated 180° about the y-axes (Sur-
face_Back).
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against complete rPhl p 7, the N-terminal peptide 1 or the
C-terminal peptide 2 (Fig. 4A) to inhibit the binding of
mAb102.1F10 to Phl p 7. We obtained the highest level of
inhibition of binding of mAb102.1F10 to Phl p 7 with rabbit
antibodies raised against complete Phl p 7 (i.e. 46.23%)
(Fig. 4B). An almost equal level of inhibition was achieved
with rabbit antibodies raised against the C-terminal portion
of Phl p 7 (i.e. peptide 2) (Fig. 4B). No relevant inhibition
(12.21%) was obtained with a rabbit antiserum specific for
the N-terminal peptide 1 or with a control antiserum
(Fig. 4B).
Structural analysis indicates that binding of mAb102.1F10 to
EF-hand allergens depends on a small number of amino
acids
Our binding experiments revealed that mAb102.1F10 shows
a rather selective recognition of EF-hand allergens although
the degree of overall sequence identity among the EF-hand
allergens was high (i.e. approximately 70%) (Table S1). In
contrast, allergic patients’ IgE reactivity showed broad
cross-reactivity with the EF-hand allergens (data not
shown). We therefore assumed that specificities of recogni-
tion may be responsible for the selective binding features of
mAb102.1F10. The second EF-hand domain appeared to be
crucial for the binding of mAb102.1F10 (Fig. 4B). We
found several amino acid differences between Phl p 7 and
EF-hand allergens that do not contribute to differences in
binding because they were identical between a
mAb102.1F10-reactive allergen (i.e. Ole e 3) and allergens
which bind with lower reactivity to mAb102.1F10 (i.e. Aln
g 4, Bet v 4, Bra r 1, Che a 3) (Fig. 5A: asterisks, yellow
part of sequences). Four amino acid exchanges were
observed only in certain allergens (i.e. Bra r 1: D, K, N;
Che a 3: S; Fig. 5A: boxed) which did not react with
mAb102.1F10, but these changes are unlikely to account for
the differences in binding because they were not exchanged
in the other allergens (i.e. Aln g 4, Bet v 4) which did not
react with mAb102.1F10. Finally, only three amino acid
exchanges remained as possible candidates for the differ-
ences in binding (Fig. 5A, B: Phl p 7: Q41, N58, S62
printed in red) because they showed relevant differences
regarding their biochemical properties between the allergens
with (Phl p 7, Ole e 3) and without (Aln g 4, Bet v 4, Bra
r 1, Che a 3) reactivity to mAb102.1F10. We therefore cal-
culated solvent-accessible surface (SAS) values for each of
the three amino acids in the dimeric three-dimensional
structures of Phl p 7 and Che a 3 (28, 37) (Fig. 5B) and
calculated the average of the corresponding residues,
because the conformation of the molecules is slightly differ-
ent in the two independent monomers of each dimer. By far
the largest changes in absolute as well as relative SAS val-
ues were observed for the change from Q41 (Phl p 7) to
R49 (Che a 3), which predisposed this residue change as the
decisive factor for the observed differences (Table 1). The
other two residue changes considered could still have an
influence due to the change in polarity/net charge, but the
change in the surface-exposed area was much less pro-
nounced.
Discussion
We have analysed epitope specificity and cross-reactivity of a
monoclonal IgG4 antibody, mAb102.1F10, which was iso-
lated from a grass pollen-allergic patient who had received
grass pollen-specific immunotherapy. mAb102.1F10 was
directed against Phl p 7, which belongs to a family of highly
cross-reactive calcium-binding EF-hand allergens occurring
in pollen of most plants. EF-hand motifs are sequences in
these allergens which contain acidic amino acids needed for
the binding of calcium. As described for allergic patients’
IgE antibodies, binding of mAb102.1F10 depended on the
presence of protein-bound calcium. In the calcium-bound
form, EF-hand allergens are supposed to expose amino acids
critical for binding of antibodies on the surface of the mole-
cule (26, 30). The binding site of mAb102.1F10 was mapped
at the C-terminal portion of the molecule containing the sec-
ond EF-hand.
Allergic patients’ IgE showed extensive cross-reactivity
with the Phl p 7-homologous allergens. By contrast,
mAb102.1F10 showed a rather selective binding to Phl p 7
and to Ole e 3, whereas only weak binding to the other EF-
Table 1 Solvent-accessible surface (SAS) of variable residues (see Fig. 5A, red) is shown for Phl p 7 (top) and Che a 3 (bottom) for both
monomer and dimer structure with the absolute SAS (in A2) as well as the relative surface exposure in the dimer (in % of the maximal sur-
face exposure of the individual residue), along with the average values calculated from both chains a and b
Chain a Chain b Average
AA SAS [A2] SAS [%] AA SAS [A2] SAS [%] SAS [A2] SAS [%]
Phl p 7
Q41_a 62.896 28.6 Q41_b 96.964 44.1 79.930 36.4
N58_a 103.388 55.3 N58_b 114.858 61.5 109.123 58.4
S62_a 60.665 40.1 S62_b 62.490 41.3 61.578 40.7
Che a 3
R49_a 181.045 62.8 R49_b 139.131 48.3 160.088 55.6
D66_a 102.104 57.7 D66_b 101.834 57.5 101.969 57.6
D70_a 85.088 48.0 D70_b 84.678 47.8 84.883 47.9
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hand allergens was observed with a more than 1000 times
lower affinity. Accordingly, mAb102.1F10 mainly inhibited
allergic patients’ IgE binding and allergen-induced basophil
activation to Phl p 7 and Ole e 3 but had little effect to the
other EF-hand allergens. When we compared the amino acid
sequences of the EF-hand allergens in the binding region of
mAb102.1F10, we could, based on the presence or absence of
reactivity to the individual EF-hand allergens, identify three
potentially crucial amino acids as candidates to justify differ-
ences between binding and nonbinding molecules. According
to calculations of the surface exposure of the three identified
amino acids in the three-dimensional structures of Phl p 7
and Che a 3, the latter of which showed highly reduced bind-
ing to mAb102.1F10, it could be confirmed that these three
amino acids showed different degrees of exposure on the two
molecules, rendering them likely candidates for the observed
binding differences. Our results thus demonstrate that a mon-
oclonal SIT-induced IgG antibody showed less cross-reactiv-
ity than allergic patients’ IgE antibodies. There are studies
indicating that also SIT-induced polyclonal IgG antibodies
show limited cross-reactivity and thus may be less cross-pro-
tective (22, 38). However, based on our data obtained for a
single SIT-induced IgG and the aforementioned SIT studies
showing limited cross-reactivity of SIT-induced polyclonal
IgG, one still cannot draw general conclusions that SIT-in-
duced IgG is less cross-reactive than allergen-specific IgE.
SIT-induced allergen-specific IgG antibodies are supposed to
contribute to the clinical success of SIT by several mecha-
nisms through inhibition of the IgE–allergen interactions
(39). In fact, SIT-induced allergen-specific IgG inhibits aller-
gen-induced basophil and mast cell activation, IgE-facilitated
allergen presentation and boosting of the IgE response. It
may therefore be assumed that the limited cross-reactivity of
therapy-induced IgG will in turn limit cross-protection
against homologous allergens from other sources. However,
also other factors besides titre and cross-reactivity such as
avidity and isotype/subclass may play a role in limited cross-
protection.
Our analysis represents only a snapshot of an individual
SIT-induced monoclonal antibody, and the success of SIT
will depend on the polyclonal IgG response and thus on the
sum and quality of the induced blocking antibodies. How-
ever, it provides a useful example and indicates that it is
important to determine the sum of epitope specificities, cross-
reactivity, titres, avidities and IgE-blocking activity of the
SIT-induced polyclonal IgG response to assess the overall
contribution to clinical efficacy.
Our findings raise the question whether there may be
differences regarding cross-reactivities of IgE and SIT-in-
duced IgG antibodies. At present, this question cannot be
answered. However, one may speculate that in the case of
SIT-treated patients, differences in epitope specificities may
be due to IgE responses induced by folded allergens and
mainly conformational epitopes, whereas injection of adju-
vant-bound allergens also induces IgG responses against
sequential (i.e. linear) epitopes. As mAb102.1F10 unlike
allergic patients’ IgE showed reactivity with the unfolded
C-terminal Phl p 7 peptide, it is quite likely that this anti-
body resulted from the induction of a de novo immune
response against the unfolded adjuvant-bound allergen in
the course of SIT and that this explains its different bin-
ding behaviour.
In conclusion, we think that our molecular analysis of the
SIT-induced IgG4 antibody provides an example that SIT
with cross-reactive allergen does not always induce cross-re-
active and cross-protective IgG antibodies.
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